Literature DB >> 1539517

Assessment of myocardial oxidative metabolism in aortic valve disease using positron emission tomography with C-11 acetate.

R J Hicks1, V Savas, P J Currie, V Kalff, M Starling, P Bergin, M Kirsch, M Schwaiger.   

Abstract

C-11 acetate has recently been introduced as a tracer of myocardial oxidative metabolism with the use of positron emission tomography. To evaluate this approach in the pressure- or volume-loaded heart, C-11 acetate clearance rate constants were determined in 22 patients with chronic aortic valve disease and in nine normal subjects. Global myocardial C-11 clearance was significantly higher in patients with predominant aortic stenosis (n = 11) or aortic regurgitation (n = 11) than in normal subjects (0.069 +/- 0.017 min-1 and 0.072 +/- 0.010 min-1 compared with 0.050 +/- 0.004 min-1, p less than 0.05) and correlated significantly with the rate-pressure product corrected for mean aortic valve gradient (r = 0.73, p = 0.0001) for all studies. However, analysis of patient subgroups demonstrated that this correlation held only for aortic stenosis (r = 0.79, p less than 0.005 for gradient-corrected rate-pressure product). Additionally, C-11 clearance was strongly correlated with the product of heart rate and mean wall stress in patients with aortic stenosis (r = 0.89, p less than 0.005) but not in patients with aortic regurgitation. Normalization of C-11 acetate clearance rate constants for gradient-corrected rate-pressure product were significantly lower in patients with loaded ventricles, particularly in the presence of a low ejection fraction, compared to normal subjects. Possible mechanisms include myocardial adaptation through hypertrophy or depressed contractility, which would both tend to reduce oxygen consumption under any given load. Serial comparison of C-11 acetate kinetics and noninvasive indexes of oxygen demand may provide assessment of disease progression in pathologic ventricular loading.

Entities:  

Mesh:

Substances:

Year:  1992        PMID: 1539517     DOI: 10.1016/0002-8703(92)90503-n

Source DB:  PubMed          Journal:  Am Heart J        ISSN: 0002-8703            Impact factor:   4.749


  6 in total

1.  Myocardial oxidative metabolism is increased due to haemodynamic overload in patients with aortic valve stenosis: assessment using 11C-acetate positron emission tomography.

Authors:  Masanao Naya; Satoru Chiba; Hiroyuki Iwano; Satoshi Yamada; Chietsugu Katoh; Osamu Manabe; Keiichiro Yoshinaga; Yoshiro Matsui; Nagara Tamaki; Hiroyuki Tsutsui
Journal:  Eur J Nucl Med Mol Imaging       Date:  2010-07-27       Impact factor: 9.236

Review 2.  Management decisions in valvular heart disease: the role of radionuclide-based assessment of ventricular function and performance.

Authors:  J S Borer; D Wencker; C Hochreiter
Journal:  J Nucl Cardiol       Date:  1996 Jan-Feb       Impact factor: 5.952

3.  Feasibility of planar myocardial carbon 11-acetate imaging.

Authors:  L J Klein; F C Visser; S A Nurmohamed; A Vink; J H Peters; P Knaapen; P S Kruijer; J D Herscheid; G J Teule; C A Visser
Journal:  J Nucl Cardiol       Date:  2000 May-Jun       Impact factor: 5.952

4.  Metabolic imaging by positron emission tomography early after myocardial infarction as a predictor of recovery of myocardial function after reperfusion.

Authors:  R J Hicks; P Melon; V Kalff; E Wolfe; R J Dick; J J Popma; E Topol; M Schwaiger
Journal:  J Nucl Cardiol       Date:  1994 Mar-Apr       Impact factor: 5.952

Review 5.  Imaging of Myocardial Oxidative Metabolism in Heart Failure.

Authors:  Masanao Naya; Nagara Tamaki
Journal:  Curr Cardiovasc Imaging Rep       Date:  2014

6.  Myocardial Oxygen Consumption and Efficiency in Aortic Valve Stenosis Patients With and Without Heart Failure.

Authors:  Nils Henrik Stubkjær Hansson; Jens Sörensen; Hendrik Johannes Harms; Won Yong Kim; Roni Nielsen; Lars P Tolbod; Jørgen Frøkiær; Kirsten Bouchelouche; Karen Kaae Dodt; Inger Sihm; Steen Hvitfeldt Poulsen; Henrik Wiggers
Journal:  J Am Heart Assoc       Date:  2017-02-06       Impact factor: 5.501

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.